Cantuzumab (CAS: 1204740-23-7) is a humanized IgG1κ monoclonal antibody that targets the CanAg antigen, a glycoform of MUC1, overexpressed in cancers like pancreatic, biliary, and colorectal cancers.
Key Features:
- Target: Binds specifically to the CanAg antigen on tumor cells.
- Mechanism: Used to create antibody-drug conjugates (ADCs) that deliver cytotoxic agents directly to tumor cells expressing CanAg.
- Therapeutic Use: Investigated for treating cancers such as pancreatic, biliary, and colorectal cancers.
Applications:
- Cancer Research: Helps to develop ADCs that target CanAg-expressing tumors, improving treatment precision while minimizing systemic toxicity.
- ADC Development: Conjugates to cytotoxic agents to form ADCs, like Cantuzumab mertansine and Cantuzumab ravtansine, which have shown effectiveness in preclinical studies.
Handling and Storage:
- Storage: Store at -20°C, away from light.
- Precautions: Use appropriate protective equipment and ensure proper ventilation during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
